Genflow Biosciences Plc (GB:GENF) has released an update.
Genflow Biosciences Plc, a UK-based biotech leader in longevity research, has announced its final results for 2023. The company, known for developing therapies aimed at preventing age-related diseases, is preparing for its Annual General Meeting and has made its Annual Report publicly available. Genflow is making strides with its lead compound, GF-1002, targeting age deceleration and treatment for chronic liver disease, with clinical trials set to begin in 2025.
For further insights into GB:GENF stock, check out TipRanks’ Stock Analysis page.
